AstraZeneca To Cut 3,000 Jobs As It Seeks To Rationalize Production Assets
CEO David Brennan tells investors the decision is another step in the company’s program to increase efficiencies.
CEO David Brennan tells investors the decision is another step in the company’s program to increase efficiencies.